Celularity Inc. Proceeds from Stock Options Exercised
Celularity Inc. (CELU) reported Proceeds from Stock Options Exercised of $108.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2026-04-30
- Celularity Inc. proceeds from stock options exercised for the quarter ending 2025-12-31 was $0.00.
- Celularity Inc. proceeds from stock options exercised for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Celularity Inc. proceeds from stock options exercised for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Celularity Inc. proceeds from stock options exercised for the quarter ending 2023-06-30 was $4.00K, a 98.32% decline year-over-year.
- Celularity Inc. proceeds from stock options exercised for fiscal 2025 was $108.00K, a 86.21% increase from fiscal 2024.
- Celularity Inc. proceeds from stock options exercised for fiscal 2024 was $58.00K, a 80.92% decline from fiscal 2023.
- Celularity Inc. proceeds from stock options exercised for fiscal 2023 was $304.00K, a 64.73% decline from fiscal 2022.
- Celularity Inc. proceeds from stock options exercised for fiscal 2022 was $862.00K, a 35.11% increase from fiscal 2021.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | $108.00K 10-K · filed 2026-04-30 | ||
| 2025-09-30 | $108.00K 10-Q · filed 2025-11-14 | |||
| 2024-12-31 | $58.00K 10-K · filed 2026-04-30 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2025-05-08 | $4.00K derived: sum of 3 quarters · filed 2025-05-08 | $304.00K 10-K · filed 2025-05-08 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-12-06 | $4.00K derived: sum of 2 quarters · filed 2024-12-06 | $304.00K 10-Q · filed 2024-12-06 | $519.00K derived: sum of 4 quarters · filed 2024-12-06 |
| 2023-06-30 | $4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-07 | $304.00K 10-Q · filed 2024-11-07 | $519.00K derived: sum of 3 quarters · filed 2024-11-07 | $918.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-03-31 | $300.00K 10-Q · filed 2024-10-16 | $515.00K derived: sum of 2 quarters · filed 2024-10-16 | $914.00K derived: sum of 3 quarters · filed 2024-10-16 | $1.15M derived: sum of 4 quarters · filed 2024-10-16 |
| 2022-12-31 | $215.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | $614.00K derived: sum of 2 quarters · filed 2024-07-30 | $852.00K derived: sum of 3 quarters · filed 2024-07-30 | $862.00K 10-K · filed 2024-07-30 |
| 2022-09-30 | $399.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-01-03 | $637.00K derived: sum of 2 quarters · filed 2024-01-03 | $647.00K 10-Q · filed 2024-01-03 | $1.06M derived: sum of 4 quarters · filed 2024-01-03 |
| 2022-06-30 | $238.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $248.00K 10-Q · filed 2023-08-14 | $663.00K derived: sum of 3 quarters · filed 2023-08-14 | $872.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $10.00K 10-Q · filed 2023-05-22 | $425.00K derived: sum of 2 quarters · filed 2023-05-22 | $634.00K derived: sum of 3 quarters · filed 2023-05-22 | |
| 2021-12-31 | $415.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $624.00K derived: sum of 2 quarters · filed 2023-03-31 | $638.00K 10-K · filed 2023-03-31 | |
| 2021-09-30 | $209.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $223.00K 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $14.00K 10-Q · filed 2022-08-09 | |||
| 2020-12-31 | $86.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $138.00K 10-K · filed 2022-03-31 | ||
| 2020-09-30 | $52.00K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |